Anemia of malignancy

E. P. Frenkel, R. L. Bick, C. J. Rutherford

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Anemia is a common association of malignant disease. It may be the first diagnostic clue to an underlying malignant disease, it may contribute to the patient's symptoms from the disease, and it may affect treatment decisions. It is important to recognize that a number of underlying mechanisms may contribute to the anemia, and to exclude those that are treatable. The recognition that tumor-associated cytokine production is a major factor in the anemia of malignancy, and that recombinant EPO can overcome this suppression, are major steps forward.

Original languageEnglish (US)
Pages (from-to)861-873
Number of pages13
JournalHematology/Oncology Clinics of North America
Volume10
Issue number4
DOIs
StatePublished - 1996

Fingerprint

Anemia
Neoplasms
Cytokines
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Anemia of malignancy. / Frenkel, E. P.; Bick, R. L.; Rutherford, C. J.

In: Hematology/Oncology Clinics of North America, Vol. 10, No. 4, 1996, p. 861-873.

Research output: Contribution to journalArticle

Frenkel, E. P. ; Bick, R. L. ; Rutherford, C. J. / Anemia of malignancy. In: Hematology/Oncology Clinics of North America. 1996 ; Vol. 10, No. 4. pp. 861-873.
@article{d05351f60b3f499697c9a25d61e65db9,
title = "Anemia of malignancy",
abstract = "Anemia is a common association of malignant disease. It may be the first diagnostic clue to an underlying malignant disease, it may contribute to the patient's symptoms from the disease, and it may affect treatment decisions. It is important to recognize that a number of underlying mechanisms may contribute to the anemia, and to exclude those that are treatable. The recognition that tumor-associated cytokine production is a major factor in the anemia of malignancy, and that recombinant EPO can overcome this suppression, are major steps forward.",
author = "Frenkel, {E. P.} and Bick, {R. L.} and Rutherford, {C. J.}",
year = "1996",
doi = "10.1016/S0889-8588(05)70373-7",
language = "English (US)",
volume = "10",
pages = "861--873",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Anemia of malignancy

AU - Frenkel, E. P.

AU - Bick, R. L.

AU - Rutherford, C. J.

PY - 1996

Y1 - 1996

N2 - Anemia is a common association of malignant disease. It may be the first diagnostic clue to an underlying malignant disease, it may contribute to the patient's symptoms from the disease, and it may affect treatment decisions. It is important to recognize that a number of underlying mechanisms may contribute to the anemia, and to exclude those that are treatable. The recognition that tumor-associated cytokine production is a major factor in the anemia of malignancy, and that recombinant EPO can overcome this suppression, are major steps forward.

AB - Anemia is a common association of malignant disease. It may be the first diagnostic clue to an underlying malignant disease, it may contribute to the patient's symptoms from the disease, and it may affect treatment decisions. It is important to recognize that a number of underlying mechanisms may contribute to the anemia, and to exclude those that are treatable. The recognition that tumor-associated cytokine production is a major factor in the anemia of malignancy, and that recombinant EPO can overcome this suppression, are major steps forward.

UR - http://www.scopus.com/inward/record.url?scp=0029899899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029899899&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70373-7

DO - 10.1016/S0889-8588(05)70373-7

M3 - Article

C2 - 8811306

AN - SCOPUS:0029899899

VL - 10

SP - 861

EP - 873

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 4

ER -